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Key Points 
 Disease progression in IGHV-M CLL with 'good-risk' cytogenetics is frequently associated with co-
evolution of 'poor risk' driver mutations and DNA methylation changes. 
 Drug resistance in IGHV-M CLL may be consequent upon the emergence of an IGHV-U clone  
Abstract 
The biological features of IGHV-M CLL responsible for disease progression are still poorly understood. We 
undertook a longitudinal study close to diagnosis, pre-treatment and post relapse in thirteen patients 
presenting with cMBL or Stage A disease and good risk biomarkers (IGHV-M genes, no del(17p) or del(11q) and 
low CD38 expression) who nevertheless developed progressive disease, of whom ten have required therapy. 
Using cytogenetics, FISH, genome-wide DNA methylation and copy number analysis together with whole 
exome, targeted deep- and Sanger sequencing, at diagnosis we identified mutations in established CLL driver 
genes in nine (69%), non-coding mutations (PAX5 enhancer region) in three, and genomic complexity in two 
patients. Branching evolutionary trajectories predominated (n=9/13), revealing intra-tumoural epi- and genetic 
heterogeneity and sub-clonal competition prior to therapy. Of the patients subsequently requiring treatment, 
two had sub-clonal TP53 mutations that would not be detected by standard methodologies, three qualified for 
the very-low risk category defined by integrated mutational and cytogenetic analysis and yet had established or 
putative driver mutations and one patient developed progressive, therapy-refractory disease associated with 
the emergence of an IGHV-U clone. These data suggest that extended genomic and immunogenetic screening 
may have clinical utility in patients with apparent good risk disease. 
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Introduction 
Clinical heterogeneity within CLL, especially in the majority of patients presenting with a low tumor burden, 
provides a continuing impetus for the discovery of prognostic biomarkers. 
Immunogenetic features such as IGHV mutation status and stereotypy, immunophenotypic markers, genomic 
abnormalities and serum markers have prognostic significance. A recently described prognostic index 
incorporating gender, age, performance status, IGHV mutation status, deletions of 11q and 17p, serum B2 
microglobulin and thymidine kinase distinguished four risk categories with differing 5-year overall and 
progression-free survivals (1). 
Candidate gene approaches and next generation sequencing have led to the discovery of mutations in many 
genes, including TP53, ATM, NOTCH1, SF3B1, BIRC3, SAMHD1, EGR2 with prognostic and/or predictive 
significance, even when first detected as small sub-clones in the case of TP53 mutation (2-10). A recent whole 
genome study demonstrated the adverse prognostic significance of multiple driver mutations and implicated 
novel non-coding mutation (11). Mutations in an intergenic region on 9p13 correlated with reduced PAX5 
expression and 3’UTR NOTCH1 mutations associated with a poor outcome comparable to cases with an exon 34 
NOTCH1 mutation. Retrospective analyses of non-trial cohorts show that integration of a restricted set of 
mutations with copy number data refines and enhances the prognostic significance of the latter and suggest 
that mutations may be incorporated into future prognostic indices (12). Furthermore, copy number array and 
next generation sequencing data inferred from a single time point or from sequential studies, have 
demonstrated intra-clonal heterogeneity in CLL, the prognostic significance of sub-clonal mutations and the 
selective pressure of therapy in determining clonal evolution (13, 14). Recent epigenetic data has identified 
three CLL subtypes that correlate with B-cell maturity and possess distinct patterns of somatic instability, 
degree of IGHV mutation, mutation risk profiles and clinical outcomes (15-18). Despite this progress there 
remain patients who would be classified as 'low-risk' based on biomarkers who nevertheless have progressive 
disease. 
To obtain more information about the genomic and epigenomic landscape and clinical significance of 
abnormalities in IGHV-M CLL (M-CLL), we performed a longitudinal study at or close to diagnosis, pre-treatment 
and post-relapse in thirteen patients. These patients presented with Binet Stage A disease (n=10) or cMBL and 
good-risk biomarkers (IGHV-M genes, no del(17p) or del(11q) and low CD38 expression), ten of whom 
subsequently required treatment. Using a combination of DNA methylation, copy number analysis, whole 
exomic sequencing (WES), targeted deep sequencing (TDR) of recurrently mutated CLL driver genes, screening 
of non-coding mutation and immunogenetic analysis, we identified the presence or acquisition of clonal or sub-
clonal driver mutations and DNA methylation changes in eight cases and the emergence of a new 
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immunogenetic clone in one case. 
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Methods 
Patient data, copy number and methylation analysis 
We studied 13 patients diagnosed at the Royal Bournemouth Hospital between 1992-2007 as cMBL or Binet 
Stage A, Rai stage 0 CLL according to the 2008 IWCLL/NCI guidelines (19). This study was approved by the local 
REC and informed consent obtained according to the Declaration of Helsinki. IGHV sequencing, CD38, 
cytogenetic and FISH analyses were performed as described (20-23) and only cases with mutated IGHV genes 
(excluding major stereotypes), low CD38 expression and lacking 11q or 17p deletion and the availability of 
stored material were included. Germline DNA (GL) was obtained from saliva (DNAgenotek). CD19+ B-cells were 
taken at a median of 1 year (0-7.3 years) from diagnosis when patients had cMBL or Stage A disease (time-point 
1 (TP1)). The three patients (pts 1-3) who did not require treatment remained as Stage A with a rising (n=2) or 
stable lymphocyte count. All three were sampled again (TP2) at a median of 7 years (6-10) from TP1 and one 
was sampled at further time-point (TP3) 3 years after TP2. In the ten patients requiring treatment, a further 
sample was taken at a median of 4 months, (range: 0-42) pre-treatment (time-point 2 (TP2)). 6/10 patients who 
relapsed after first line treatment had a sample taken post relapse (time-point 3 (TP3)) and 2/6 were also 
sampled at relapse following subsequent treatments (TP4 and 5). For 13 sample-trios (GL, TP1, TP2), DNA 
regions of copy number alteration (CNA) and differential methylation were identified using SNP6 arrays 
(Affymetrix) and 450K arrays (Illumina) respectively, as described (7, 24). 
Sequencing 
WES libraries were prepared from 13 sample-trios (GL, TP1, TP2) as described (25). TDR used Haloplex (Agilent) 
as described (26), to capture SNVs identified by WES and 22 genes (exons and 5' & 3'-UTRs) that are frequently 
mutated in CLL (Table S1) in all tumour samples. TDR libraries were sequenced at high depth (average x4000) to 
detect mutation down to the 1% level. For each mutation detected by TDR, variant allele frequencies (VAF) 
were adjusted for tumour purity estimated as %CD19+ cells. Clonal or sub-clonal mutations were further 
classified according to (26). We subjected the TDR data to SciClone analysis (27) to define the clonal dynamics 
of mutation clusters into three types: 1) Static: clusters remain the same over time. 2) Expanding: all mutations 
in a cluster increase over time. 3) Evolving: new mutations in later samples or one or more mutations in a 
cluster increase over time. Phylosub was used for tumour phylogeny analysis to predict the most likely order of 
mutation events and classify either linear or branching evolution patterns (28). PAX5 enhancer region was 
screened as described in (11). We defined mutated genes into those recurrently mutated from previous CLL 
studies, non-coding mutation and genes mutated in other hematological malignancies (All excluding copy 
number changes). Supplementary methods are available on-line.  
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Results 
Genomic landscape of progressive M-CLL  
Clinical features, treatment regimens and the genomic landscape at multiple time points are summarized in 
Table 1 and Figure 2. 
We employed WES and TDR to identify somatically-acquired mutation in tumour samples from 13 cases with 
mean coverage of 77x (min-max: 43-127) and 3681x (2142-5268), with more than 86% of all bases covered at 
>20x and >200x, respectively. (Figure 1, Tables S2 and S3). Of the filtered WES variants (Table S4), TDR 
confirmed the presence of 224/312 (72%) SNVs and 7/9 (78%) indels (when present at both TP1 and TP2), 
respectively (Table S5 and Supplementary methods). We used the TDR variants to study temporal clonal 
evolution and demonstrated that our TP1 and TP2 samples harbored a similar mutation burden, with on 
average 17 (min-max: 9-26) and 19 (8-29), respectively. After adjusting for tumour purity, we observed no 
difference in the mean number of clonal (6 v 6) or sub-clonal mutations (10 v 12) in either untreated time-point 
(TP1 v TP2). All reported variant allele frequencies (%VAF) are adjusted for tumour purity. 
Focusing on genes previously shown to be recurrently mutated in CLL; at TP2, clonal mutations were detected 
in MYD88 (p.L265P) (pt-2), and CHD2 (pt-1) among the 3 untreated patients and in ATM (pt-4), DDX3X (pt-13), 
NOTCH1 (pts-6,13), SF3B1 (pts-6,8), TP53 (pts-8,9), NFKBIE (pt-5), SPEN (pt-9), ZMYM3 (pt-6), KLHL6 (pt-10), 
BIRC3 (pt-13) and IRF4 (pt-13) among the 10 patients who received treatment. Only five of these mutations 
were clonal (Figure 2). In addition, three patients (pts-3,11,12) exhibited missense mutations (damaging by 
Polyphen-2) in genes known to have a role in other hematological tumors, LTF (pt-3), ITGA6 (pt-11) and a 
frame-shift in TNFAIP3 (pt-12) and all were present at sub-clonal levels (11-42 %VAF). Only one case (pt-7) 
lacked any recurrently mutated driver mutation documented in CLL or other hematological malignancies. 
However, WES did identify ten mutated genes from which two candidates emerged, namely missense 
mutations in ZBTB7C a kidney cancer-related gene that interacts with p53 (ref: 29) and S1PR4 a receptor 
expressed in hematopoietic cells that interacts with MAPK3 (ERK1), placing it in the B-cell receptor pathway 
(30).  
The CLL driver mutations (with the exception of BIRC3 in pt-13) were detectable (by the presence of one or 
more mutated reads) at TP1 supporting the hypothesis that identification of mutations at diagnosis may 
identify individuals later requiring therapy. The CLL driver gene mutations with VAFs <1% (IRF4, NOTCH1, SF3B1 
and TP53; in pts-6,8,9,13) at TP1 were ascertained by manual curation of the TDR sequencing reads (Table S6) 
after being originally detected in later tumour time points with a higher VAF, suggesting a larger sub-clonal 
population at progression. Pileup of reads across all samples provided statistical confidence for calling TP53 
mutation in patient-8 and 9 below a 1% VAF (P=0.013 & <0.001; Table S6). Droplet-digital PCR analysis of 
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patient-13 confirmed the presence of the NOTCH1 mutation at TP1 (Figure S1). Together, this would suggest 
sequencing depths much greater than x4000 will be required to robustly identify all sub-clonal mutations, for 
example, patient-8 had a TP53 mutation (29 %VAF) at TP2, detectable at TP1 in 9/15581 reads (0.1 %VAF), 
equating to the presence of one mutant cell in ~1000 CLL B-cells. In patient-13, the BIRC3 mutation at TP2 was 
not identified at TP1 (0/3624 reads) and conversely a clonal DDX3X mutation at TP1 was detected as a small 
sub-clone at TP2. This lead to a re-appraisal of this case which is discussed in detail later. At relapse, we 
identified mutations in SF3B1 (pt-6) and TP53 (pt-9) with VAF's of 17 and 3.3% respectively which had VAF's of 
<1% pre-treatment. 
We screened for non-coding mutations (11). PAX5 enhancer region mutations were detected in three patients, 
estimated at TP1 to be clonal in one case (pt-4) and sub-clonal in the other cases (pts-2,6) (Figure 2 and S2). 
These mutations co-occurred with other mutations: MYD88 (pt-2), ATM (pt-4) and NOTCH1, SF3B1 and ZMYM3 
(pt-6). We also detected at TP2, the presence of a sub-clonal mutation (6 %VAF; chr17:56408615:T>C) in the 
mature sequence of hsa-mir-142, this co-occurred with a ITGA6 mutation in patient-11 (Figure S2). The NOTCH1 
3’UTR mutations, previously observed solely in cases of U-CLL (11), were absent. 
Combining karyotypic, FISH and SNP6 data, at TP1, only two patients (pts-8, 10) had no copy number 
abnormality or translocation, while the remainder had mono (n=5) or mono + biallelic loss of 13q14. Two 
patients (pts-12,13) with del13q also had trisomy 12. Two patients (pts-6,9) had a complex genome (3 CNAs), 
defined as previously reported (31). SNP6 confirmed the absence of 11q or 17p deletion (Table S7). At TP2, 
additional abnormalities were detected in 3 patients (pts-4,5,8). Interestingly, the complex karyotypic 
abnormality in patient 8 was associated with expansion of a sub-clonal TP53 mutation (from 0.1% at TP1 to 29% 
at TP2) without TP53 loss. Three patients (pts-2,4,5) had an unbalanced translocation. Patient-13 had a 
remarkable change in copy number and is discussed later. 
Intra-clonal heterogeneity in progressive M-CLL 
Our longitudinal approach provided an opportunity to evaluate intra-clonal heterogeneity both before and 
following therapy. 
SciClone analysis of TP1 and TP2 data from patients prior to therapy, enabled us to make the following 
observations: 1) Four cases (pts-5,7,10,12) had a static sub-clonal structure with mutation clusters present at 
similar VAFs at both time points (pt-12 in Figure S3A). 2) Two cases (pts-2,4) had an expanding population 
where all mutations in a cluster were more dominant at TP2 (pt-4 in Figure S3A). 3) Seven patients (pts-
1,3,6,8,9,11,13), had an evolving genome where new mutations appeared (n=8 in 4 patients (pts-6,8,9,13) 
and/or one or more mutations in a cluster increased, at TP2 (pt-6 in Figure S3A). Six of these new mutations 
had low read depths (< x4000; ranging: 138-3642) in TP1 samples, suggesting there may be a lack of detection 
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sensitivity. The three remaining mutations (DSG4, SIM1, SLC8A2) had adequate depth (4218-9043) at TP1, 
suggesting these mutations are either very rare (in <0.5-1% of cells) or represent acquired mutations at disease 
progression (TP2). For the six patients with post therapy time points, there were no new mutations and we 
observed two patients (pts-5,12) exhibiting a static structure with same distribution of sub-clones pre- and 
post-treatment (pt-12 in Figure S3B), while four cases (pt-4,6,9,13) showed expansion (pt-4 in Figure S3B) or 
evolution (pt-6 in Figure S3B) following an apparent therapy-related sweep selecting resistant/fitter sub-clones. 
Interestingly, these four cases had either expanding or evolving mutation clusters before therapy. Results for 
the remaining patients are provided in Supplementary Figure S4. 
Phylosub analysis predicted a linear evolutionary path, where progeny replaced ancestral clones, in a minority 
of patients (n=4) in whom SciClone analysis had identified either static (pts-7,12) or expanding (pts-2,4) 
mutation clusters. Phylosub also predicted that the ATM, MYD88, S1PR4, TNFAIP3 and ZBTB7C mutations in 
these patients were early evolutionary events (placed in the 1st or 2nd nodes of each tree). Complex branching 
trajectories were predicted in the remaining 9 patients, including two of the three patients (pts-1,3) with no 
indication for therapy, and provided the following insights: 1) The BCL2, CHD2, NOTCH1, SF3B1 and TLR4 
mutations were all predicted to be early events. 2) Generally located at branch points, the sub-clones that 
appear to have good fitness, or are selected for at later tumour time-points, contained CLL drivers (ITPKB, 
NFKBIE, SF3B1, TP53, ZMYM3) or genes mutated in other haematoloical malignancies (ITGA6, LTF) supporting 
the role of genes in the latter two categories as candidate drivers of progression in those patients. 3) 
Convergent evolution was only found in two patients (pts-4,8) who exhibited two mutations in a single gene 
(ATM:p.I2606M/p.Q2733K and IGLL5:p.C31Y/p.P50S). All four mutations were clonal and only the IGLL5 
mutations were close enough to be detected on separate overlapping reads, but as the VAFs were similar (54-
57%) they could have arisen in the same cell. 
Phylosub and SciClone analysis of patients-4,6,9 and 12 is displayed in Figure 3. These four patients had three 
(pts-4,6,12) or four (pt-9) tumour time-points presenting static, expanding or evolving mutation clusters with 
predicted linear (pt-4,12) or branching (pts-6,9) evolution trajectories before and after therapy. At TP2 in 
patient-4 we observe expanding populations (nodes C-E) replacing the ancestral population, suggesting that 
these later mutations are associated with disease progression. Following treatment with bendamustine plus 
rituximab (BR) (TP3), we observed no reduction in population frequencies. Conversely, in patient-12, we 
observed a reduction back to baseline (TP1) for nodes C-E, suggesting a similar sensitivity of the descendant 
clones to Chlorambucil-Rituximab therapy; this patient remains in remission. Interestingly, in patient-6 the 
ITPKB, SF3B1 and ZMYM3 mutations were predicted to be in distinct populations (nodes I, J and E, respectively) 
and following chlorambucil treatment at TP3 the population frequencies of both the I (ITPKB) and J (SF3B1) 
nodes increased in comparison to other nodes. In patient-9 following two rounds of therapy (chlorambucil and 
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BR) we observed 75% del(17p) loss by FISH and a sub-clonal TP53 mutation (p.Y234C, 3.3 %VAF), at TP4. A 
complex karyotype was also observed at TP3. The difference between del(17p) FISH clone size and %VAF of the 
TP53 mutation would suggest evolutionary independent events, with a rare TP53 mutated clone detectable at 
presentation and later acquisition of del(17p) loss in another TP53-wildtype clone. Following exposure to 
chemo-immunotherapy, the resistant TP53 aberrant clones accumulate and dominate the tumour. Phylosub 
results for the remaining patients are provided in Supplementary Figure S4. 
The emergence of an IGHV-U immunogenetic clone can drive progression 
Substantial differences in the clone size of CNA's and mutations between TP1 (diagnosis) and TP2 (+8 years) in 
patient-13, and the detection of a BIRC3 mutation only at TP2, led to a review of karyotypic, FISH, SNP6 and 
mutational data and targeted re-sequencing analysis of samples taken after treatment with chlorambucil, BR 
and ofatumumab, all of which were ineffective. This showed a remarkable temporal shift in genomic 
aberrations supporting a dominant population at diagnosis containing a deletion of 13q, loss of chromosome Y 
and a unique set of mutations, including DDX3X, HEPH, RARB and TEC. These were gradually replaced by a 
47,XY, trisomy 12, population with mutations in 18 genes including BIRC3, NOTCH1 and IRF4 (Figure 4 and 
Table S8). As the dominant mutations present at TP2 are more frequently or exclusively associated with IGHV-U 
genes, we reanalyzed the IGHV status at TP2, and identified a dominant IGHV5-10-1*01 (100% identity to germ-
line) clone in addition to the IGHV3-48 clone with 92% germ-line identity present at diagnosis. IGHV analysis of 
six intermediate samples between TP1 and 2 detected the IGHV-U clone as far back as 4 years post diagnosis 
(Table S9). Importantly, both the NOTCH1 mutated and trisomy 12 sub-clones were detectable at diagnosis 
using TDR and FISH respectively, demonstrating the presence of the IGHV5-10-1*01 clone at diagnosis but at a 
level which was undetectable using standard immunogenetic assays. This patient's tumour eventually 
transformed to a diffuse large B-cell lymphoma, using the IGHV5-10-1*01 clone. Unfortunately, TDR of the 
Richter's node biopsy was not successful. 
Additional IGHV sequencing on the other cases failed to identify any additional patients with evolution of an 
IGHV-U clone (Table S9). 
DNA methylation subtyping and co-evolution of epigenetic changes 
We performed clustering analysis of the TP1 methylation data together with a reference sample set where the 
three epigenetic subtypes were defined previously (Oakes, in press) (32) and determined that 12/13 patients 
belonged to the high-programmed CLL DNA methylation subtype, consistent with the selection of our patients 
based on the presence of mutated-IGHV (Figure S5A). In all except a single patient, adjacent clustering of the 
TP2 data confirmed the clonal relationship between tumour time-points. The exception was patient 13 which 
clustered in the low-programmed CLL subtype at TP2, consistent with the emergence of the IGHV-U clone. 
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Patients with limited genetic evolution had relatively few differences in overall methylation, where as those 
that exhibited either expansion or evolution of genetic sub-clones showed higher proportions of altered CpG 
methylation (Figure S5B). 
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Discussion 
Patients with IGHV-M genes, defined as <98% identity to the germ-line sequence, have a better outcome than 
those with IGHV-U genes (33, 34). While stable cMBL and Stage A CLL are strongly enriched for cases with M-
CLL, 37-39% of patients entered into the UKCLL4 and CLL8 trials of first line therapy had M-CLL (35, 36) and the 
key biological features responsible for progression are still poorly understood (11). M-CLL is biologically 
heterogeneous and studies have shown that CD38, CD49d and ZAP70 expression, serum markers, stereotypic 
subset-2 (37), telomere length, del(11q) and del(17p), and genomic abnormalities, influence time to first 
treatment or outcome following therapy (38-43). In this study, we performed longitudinal genomic and 
epigenomic characterization before and after therapy in a cohort of M-CLL cases presenting with Stage A 
disease or cMBL. All cases lacked established biomarkers associated with progression: namely, high CD38 
expression, del(11q), del(17p). Nevertheless, 10/13 cases subsequently required treatment. 
Prior to treatment we found mutations in genes that are recurrently mutated in CLL, (ATM, BIRC3, CHD2, 
DDX3X, IRF4, ITPKB, KLHL6, MYD88, NOTCH1, NFKBIE, SF3B1, SPEN, TP53 and ZMYM3) in nine patients (69%) 
with a mean of one mutation per case (min-max: 0-4). This mutation incidence is consistent with a recent whole 
genomic and exomic study, where 83% of M-CLL cases had a driver mutation (11). Nine patients had one or 
more clonal mutations detected pre-treatment and the majority of the sub-clonal mutations were detectable at 
the earliest time-point at or soon after diagnosis. While many of the above genes are associated with disease 
progression and/or resistance to treatment, the clinical significance of others (ITPKB, KLHL6 and SPEN) is less 
certain. A further three patients had mutations in other genes (LTF, ITGA6 and TNFAIP3) implicated in other 
haematological malignancies (COSMIC v 73) (Ref: 44). 
We also screened for non-coding mutation in the PAX5 enhancer region. These mutations co-existed with 
MYD88, ATM, NOTCH1, SF3B1 and ZMYM3 mutations in contrast to the original description where they were 
either the sole recurrent mutation or occurred in conjunction with 13q loss (11). 
SciClone and Phylosub analysis provided novel insight into the extent of intra-clonal heterogeneity. Clonal 
expansion or evolution, predominantly in a branching pattern, was found in nine cases pre-treatment, 
indicating that sub-clonal competition occurs in the absence of selective pressure through therapy, with the 
resistant/fitter sub-clones dominating the tumour at post therapy time-points. A recent WES study comparing 
matched pre-treatment and relapse samples demonstrated that clonal evolution was the rule after therapy and 
the resistant clone could be detected before treatment in ~30% of cases (14). Six cases developed isolated 
splenomegaly, two had splenomegaly and lymphadenopathy and two had lymphadenopathy prior to 
treatment. Further spatial-temporal studies will be required to determine the site(s) of clonal evolution. 
Phylosub analysis also demonstrated the selection of sub-clones containing either SF3B1, TP53, ITGA6, ITPKB, 
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LTF, NFKBIE, or ZMYM3 mutations, supporting their role as candidate drivers of progression. 
One unexpected finding was the emergence of an IGHV-U clone in one patient who after six years of stable 
disease, developed progressive, therapy-refractory disease, culminating in a clonally-related lymphomatous 
transformation. Each clone had a unique spectrum of gene mutations and epigenetic profiles consistent with 
two distinct and competing leukemic clones originating from a different pool of lymphocyte progenitors. Bi, or 
more rarely multi-clonal IGHV rearrangements have been documented. From a cohort of 1147 cases, Plevova et 
al, identified seven cases with both mutated and unmutated clones in which serial studies showed diminution 
of an IGHV-M clone with persistence of a co-existing IGHV-U clone, resulting in re-classification to U-CLL (45). 
Clinically, this was associated with progressive lymphocytosis, disease progression and in some cases, the 
selection of a TP53-defect post therapy. Our case is unusual in that the unmutated clone was not detectable 
until 4 years after diagnosis using standard methodologies for IGHV sequencing, even though a sub-clonal 
trisomy 12 and NOTCH1 mutation, associated with the unmutated clone were detected at diagnosis using more 
sensitive techniques. 
Previous whole genome longitudinal studies of copy number (46-48) and/or genomic mutations (49-52) in CLL 
have included a higher percentage of cases with U-CLL than M-CLL and with progressive rather than stable 
disease. However, a picture has emerged of clonal evolution which is usually branched rather than linear and is 
more frequent in cases with progressive disease who have required treatment for which the majority of driver 
mutations can be detected at initial testing, often as small sub-clones. Our study confirms many of these 
findings but also highlights the high frequency of CLL driver mutations in a progressive cohort miss-labelled as 
'good-risk' and the extent of clonal evolution prior to therapy. DNA methylation analysis revealed that co-
evolution of genetic and epigenetic changes is a prominent feature and that this exists regardless of IGHV 
subtype and mutational risk assessment, supporting the perspective that evolution is an important predictor of 
disease progression (13, 14). A recent study (53) also found the highest number of differentially-methylated 
CpGs were in cases with genetically evolving and expanding sub-clones. 
From a clinical perspective, a key question is whether the additional information that genomic and epigenomic 
screening provides in this group is likely to improve patient outcome. While it would be unwise to draw general 
conclusions from this small study, it does offer three examples where screening could have clinical utility. 
Firstly, 2/13 cases had small TP53 mutated clones early in the disease with evidence of clonal selection post 
therapy. These cases had no TP53 loss detectable by FISH when the mutant clone was initially detected. 
Secondly, 6/11 cases with 13q loss fell into the 'very-low' risk category defined by Rossi at al, in which 
predominantly IGHV-M cases with isolated 13q loss, lacking mutations in TP53, BIRC3, NOTCH1, SF3B1 and 
MYD88 had a prolonged TTFT and an expected OS similar to the matched general population (12). Two of our 
six cases with isolated 13q loss had a progressive lymphocytosis with no indication for treatment and a 
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mutation in CHD2 or LTF while three of the four who required treatment, had mutations in NFKBIE, TNFAIP3 or 
ITGA6, suggesting that more extensive screening may aid in the differentiation of cases destined to have stable 
or progressive disease. Finally, the emergence of an IGHV-U clone, not evident at diagnosis, which eventually 
lead to the patient's death is a rare event but supports either repeat immunogenetic analysis in cases with 
unexplained progressive or therapy-refractory disease, or the use of more sensitive assays capable of detecting 
small clones. In summary this study does not evaluate the role of other factors such as cell signalling as an 
explanation for disease progression, but does support the role for sequential genomic/epigenomic screening as 
a means of identifying potential driver mutations and predicting progressive disease. 
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Figure Legends 
Figure 1: Study overview 
(A) Inclusion criteria for study and definition of disease progression. (B) Tumour time point sampling time line 
for the 13 patients. Tx = treatment. (C) Flow diagram describing genomic analyses and result summaries. WES = 
Whole Exome Sequencing. TDR = Targeted Deep Re-sequencing. Example data plots for SciClone mutation 
clustering, Phylosub phylogenetic trees and concentric pie charts (each layer, inner to outer, is a sampling time 
point) displaying imputed SNV population frequencies at each phylogenetic node. *For indel filtering we 
accepted a high-false positive WES rate to ensure we could capture all of the 'true' somatically-acquired indel 
variants by TDR (Supplementary methods). When considering indels present in 2 or more tumour time-points 
(2+TPs) our indel TDR validation rate (78%, 7/9%) was in line with the SNV rate (72%). 
Figure 2: Heat-map representation of tumour time-points analysed by WES and targeted deep re-sequencing 
From top to bottom: Key to heat-map cell shading. Patient characteristics, light blue cell shading indicates 
patients with follow-on tumour samples (ie. TP3, TP4, TP5); dark grey cells indicated a positive result. Sub-
clonal (light green cells) and clonal mutations (dark green cells) in each patient, grouped into recurrently 
mutated CLL driver genes, non-coding mutation described in Puente et al (6) and genes mutated in 
haematological malignancies. Numbers in cells denote tumor purity-adjusted %VAFs from TDR. SC = sub-clonal, 
C = Clonal from Sanger-seq traces. Presence of multiple productive-IGH relating to patient-13, chromosomal 
translocation or genome complexity is denoted by dark grey cells. SNP6.0 data for TP1 and TP2 samples. 
Figure 3: PhyloSub analysis of TDR results in predicted linear and branching clonal evolutionary pattern 
By columns (A) Two patient examples (pt-12 and 4) of linear evolution path, (B) Two patient examples (pt-6 and 
9) of complex branching trajectories. (A) & (B) top panel: XYZ scatter-graphs displaying the SciClone mutation 
clustering analysis on TDR datasets from sequential tumour time points TP1 (x-axis; first tumour sample), 2 (z-
axis; progression) and 3 (y-axis; post-treatment). Data point symbols denote a distinct mutation cluster and the 
x=y=z line is displayed as a dashed blue arrow and denotes no change in the tumor purity-adjusted %VAF of 
mutation clusters between time points (clonal equilibrium). Selected gene symbols are displayed adjacent to its 
corresponding mutation cluster. (A) & (B) bottom panel: Concentric pie charts (each layer, inner to outer, is an 
early to later sampling time point) displaying imputed SNV population frequencies at each phylogenetic node. 
Predicted phylogenetic tree structure (best model shown), with population frequencies for each node from 
Phylo-sub analysis. Blue and red boxes denote large changes SNV population frequencies prior to and after 
first-line treatment, suggesting ongoing clonal dynamics and selection by therapy, respectively. Selected gene 
symbols are displayed adjacent to the corresponding segment of the pie chart or phylogenetic node. 
Figure 4: Evolution of multiple productive-IGH in CLL patient 13 
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(A) From top to bottom: Five tumour time points with corresponding clinical, cytogenetic and immuno-genetic 
data. Mutation heat-map representation of five tumour time-points analysed by targeted deep re-sequencing. 
Numbers in cells denote tumor purity-adjusted %VAFs from TDR. Cell colours are linked to the SNV population 
nodes/frequencies displayed in part B and C. Lighter shading indicates a sub-clonal mutation. Blue 
asterisks/del13q14 = M-CLL clone (IGHV3-48; 92% identity to germ-line; del(13q14)) and Red 
asterisks/Trisomy12 = U-CLL clone (IGHV5-10*01; 100% identity to germ-line; Trisomy 12). (B & C) Filled light 
blue and red boxes denote mutations and cytogenetic abnormalities inferred into the M-CLL and U-CLL clone, 
respectively. From left to right: Concentric pie charts (each layer, inner to outer, is an early to later sampling 
time point) displaying imputed SNV population frequencies at each phylogenetic node. Predicted phylo-genetic 
tree structure, with population frequencies for each node from Phylo-sub analysis. Best models are displayed 
for analyses using all mutations (B) or only mutations associated with either the M-CLL or U-CLL clone providing 
insights into the probable order of mutation (C). Note from TP3 onwards the mutations associated with the M-
CLL clone are not detectable by sequencing. Open blue and red boxes denote large changes SNV population 
frequencies prior to and after first-line treatment, suggesting ongoing clonal dynamics and selection by therapy, 
respectively. 
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Supplementary Tables: 
Table S1: List of the 22 genes frequently mutated in CLL that were captured and resequenced by TDR  
Table S2: Whole exome sequencing quality metrics and coverage statistics 
Table S3: Targeted deep sequencing quality metrics and coverage statistics 
Table S4: 786 mutations identified by whole exome sequencing 
Table S5: Targeted deep sequencing validation of whole exome sequencing mutations 
Table S6: Manually-curated established or putative mutations from the TDR data  
Table S7: SNP6.0 copy number data  
Table S8: Sequential targeted deep sequencing on patient 13 
Table S9: Sequential IGHV analysis 
Supplementary Figures: 
Figure S1: Droplet-digital PCR analysis of the NOTCH1 delCT mutation in Patient-13. (A-C) X/Y-scattergraph of 
mutant positive (blue), mutant-wildtype double-positive (orange), wildtype positive (green) and negative 
droplets (black) Pinks lines are user-defined thresholds for each droplet cluster (D) Fractional abundance of 
mutant droplets in Germ-line, tumour TP1 and TP3 gDNA template from Patient-13 and a NGS NOTCH1 
wildtype CLL control sample (E) Table displaying the droplet number for each sample in D and fractional 
abundance estimates (with 95% Confidence Intervals). 
Figure S2: Non-coding mutation 
(Left panel) Sanger-sequencing verified PAX5 enhancer region somatically-acquired mutations in three patients. 
Mutated base-pairs highlighted in green. Patients 2 and 6 have sub-clonal mutations at TP1. Patient-4 had a 
clonal mutation (overlapping base peaks) at TP1. (Right panel) A sub-clonal hsa-mir-142 mutation identified in 
whole exome sequencing (WES) data from patient 11 at disease progression (TP2). Mutated sequencing reads 
identified by blue C bases (6% VAF, 3/51 WES reads). Human mir-142 RNA sequence and mutation site in 
brackets. The red arrow indicates the position of the mutated base ( on the mature micro RNA hairpin 
molecule. 
Figure S3: SciClone analysis of mutation clusters pre and post first-line therapy 
XY scatter-graphs display the SciClone mutation clustering analysis performed on TDR datasets from sequential 
tumour time points in columns (A) before therapy and (B) after first-line treatment for three example patients 
displaying either a static (pt-12; treated with Chlor R. TEX13B data point not displayed as it resides on Chr X), an 
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expanding (pt-4; BR) or an evolving (pt-6; Chlor) form of clonal dynamics prior to and after treatment. Data 
point symbols denote a distinct mutation cluster and the x=y line is displayed as a dashed arrow and denotes no 
change in the tumor purity-adjusted %VAF of mutation clusters between time points (clonal equilibrium). 
Selected gene symbols are displayed adjacent to its corresponding mutation cluster. 
Figure S4: SciClone and Phylosub results for the remaining patients 
(Left panel) XY scatter-graphs display the SciClone mutation clustering analysis performed on TDR datasets 
from sequential tumour time points TP1 (x-axis; first tumour sample) vs TP2 (y-axis; progression sample). Data 
point symbols denote a distinct mutation cluster and the x=y line is displayed as a dashed arrow and denotes no 
change in the tumor purity-adjusted %VAF of mutation clusters between time points (clonal equilibrium). 
Selected gene symbols are displayed adjacent to its corresponding mutation cluster. The table displays TDR 
%VAFs for each mutation, read depths, SciClone cluster assignment and probabilities (Right panel) Predicted 
phylogenetic tree structure (best model shown), with tumour time-point (TPn) population frequencies for each 
node from Phylo-sub analysis. 
Figure S5: Programmed epigenetic subtypes and longitudinal stability of DNA methylation patterns 
(A) Co-clustering heat-map of the top 1,000 most variable CpGs across all patient samples (black boxes and 
bracketed numbers) and 127 CLL cases (open boxes) previously assigned to one of the three primary epigenetic 
subtypes (12) termed: high (red dendrogram/boxes), intermediate (yellow dendrogram/boxes) and low (green 
dendrogram/boxes) programmed CLLs (HP-, IP-, and LP-CLLs, respectively). 12/13 cases clustered with HP-CLLs 
(patient-8 resides in IP-CLL group) and both time-points cluster adjacently, except for patient-13 where TP2 
sample clusters with the LP-CLLs. Blue = hyper-methylated CpG, White = hypo-methylated CpG. 
(B) Stacked bar chart of % of CpGs different between TP1 and TP2 450K DNA methylation datasets. Hyper- and 
hypo-methylation differences (Blue and white bars, respectively) of greater than 10% (out of a total of 459,625 
CpGs analyzed) were tallied per case and were adjusted for differences in tumor cell content and copy number 
changes between samples. Patients are grouped by their genomic evolution status from SciClone analysis 
(Static, Expanding and Evolving). Patient-11 has a small % methylation difference probably corresponding to the 
evolution of only a minor sub-clonal mutation cluster at TP2 (cluster #3; See supplementary figure S2). 
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Table 1: Overview of patient biomarker and clinical data 
 
Tumour time point 1 Tumour time point 2 
 
  
Patient 
ID 
Age at 
Diagnosis 
IGHV 
(% 
identity) 
FISH/Karyo 
%CD38 
expression 
Lymphocyt
e Count 
(x10^9/L) 
IGHV 
(% 
identity) 
FISH/Karyo 
%CD38 
expression 
Lymphocyte 
Count 
(x10^9/L) 
LDT 
1st 
Treatment 
(Response) 
Treatment 
at relapse 
(Response) 
Current 
Status at last 
follow up 
(03/8/15) 
1 52 
IGHV4-
61 (93%) 
del13q +/- (54%) 2 6 
IGHV4-61 
(93%) 
del13q +/-,-/- (10, 
85%) 
1 142 > 1 yr - - Stable CLL 
2 72 
IGHV3-
73 (91%) 
del13q  
46, XY, 
der4(4)t(4;12)(q35;q
13) 
1 5 
IGHV3-73 
(91%) 
 no change 1 25 > 1 yr - - Stable CLL 
3 57 
IGHV2-
70 (93%) 
del13q +/- (90%) 1 92 
IGHV2-70 
(93%) 
no change 1 88 > 1yr - - Stable CLL 
4 61 
IGHV4-
59 (89%) 
del13q +/- (6%) 
45,X -Y, 
t(7,13)(a11.2;q14) 
15 34 
IGHV4-59 
(89%) 
del13q +/-,-/- (76, 
8%),  
45, X –Y, 
t(7;13)(q11.2;q14) 
50 136 > 1 yr BR (CR) - 
High risk 
MDS. Died. 
5 79 
IGHV4-
61 (92%) 
del13q +/-,-/- 
(9/86%) 
46, XY, 
t(6;13)(q26;q14) 
1 107 
IGHV4-61 
(92%) 
del13q +/-,-/- 
(14/86%) 
46, XY, 
t(6;13)(q26;q14) 
- 198 > 1 yr Chlor (CR) BR (PR) Stable CLL 
6 70 
IGHV3-
48 (97%) 
del13q +/- (88%) 1 20 
IGHV3-48 
(97%) 
del13q +/-,-/- (53, 
10%) 
2 127 
6-12 
months 
Chlor (GR) BR (CR) In remission 
7 47 
IGHV4-
34 (92%) 
del13q +/-,-/- (19, 
72%) 
6 59 
IGHV4-34 
(92%) 
no change 1 81 > 1 yr Chlor R (PR) 
Alemtuz (CR, 
MRD +ve) 
In remission 
8 59 
IGHV3-
23 (96%) 
normal 3 21 
IGHV3-23 
(96%) 
del13q +/- (66%) 46, 
XY, 
del(9)(q21),t(12;15)(p
11;q15)  
1 48 > 1 yr 
Chlor Of 
(CR) 
- In remission 
9 74 
IGHV3-7 
(89%) 
del13q +/- (54%) 1 17 
IGHV3-7 
(89%) 
del13q +/- (91%)  
(+ del17p at TP3) 
1 185 
6-12 
months 
Chlor (PR) BR (CR) On Ibrutinib 
10 56 
IGHV3-
48 (93%) 
normal 5 181 
IGHV3-48 
(93%) 
no change 2 139 > 1 yr Chlor (PR) Continuum Stable CLL 
11 64 
IGHV3-
23 (91%) 
46 XY. No 13q FISH 1 58 
IGHV3-23 
(91%) 
NT 1 145 > 1 yr B Of (CR) - In remission 
12 63 
IGHV4-
34 (96%) 
47 XY,+12. No 13q 
FISH 
1 42 
IGHV4-34 
(96%) 
NT 1 77 
6-12 
months 
Chlor R (CR) 
BR (CR, MRD 
+ve) 
Continuum 
In remission 
13 67 
IGHV3-
48 (92%) 
tri 12 (2%) 
del13q -/- (55%) 
  
9 18 
IGHV3-48 
(92%) & 
IGHV5-
10-1*01 
(100%) 
tri 12 (73%) 
(tri 12 (75%) at TP3) 
21 158 > 1 yr Chlor (NR) 
BR (PR), Of 
(PR) 
Richters 
Syndrome, 
NR to CHOP 
Of. Died. 
Footnote: bold Patient ID = not treated by last follow up. NT = Not tested. LDT = Lymphocyte Doubling Time (from diagnosis for the first year of follow-up) 
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A B
Stage	  of	  disease:
Binet Stage	  A	  (n=10)
cMBL (n=3)
Biomarker	  Profile:
IGHV-­‐mutated
No	  TP53 abnormality
No	  del(11q)
Low	  CD38	  expression
Disease	  Progression:
First-­‐line	  therapy	  (n=10)
OR
Rising	  lymphocyte	  count	  (n=3)
Availability	  of	  
post-­‐treatment	  material	  (n=6)
4
5
8
9
2
12
3
13
0 2 4 6 8 10 12 14 16
Years	  from	  diagnosis
TP1
TP2
Key:
TP3
TP4
TP5
11
10
6
1
Untreated
Treated
Tx
Tx
Tx
Tx
Tx
Tx
Tx	  =	  Treatment
C
WES/SNP6.0
Exome-­‐seq mean	  
coverage	  77x	  (range	  
43-­‐127).	  86%	  bases	  
covered	  at	  >20x
Samples:
TP1	  &	  2	  tumors	  
(n=13	  &	  13)
TDR
All	  WES	  variants	  and	  
exon	  re-­‐sequencing	  of	  
22	  CLL	  genes.
Mean	  coverage	   3681x	  
(range	  2142-­‐5268)
95%	  of	  all	  bases	  
covered	  at	  >200x
Samples:	  
All	  tumor	  time	  points	  
(n=	  36)
Bioinformatic
analyses
1)	  Purity	  adjustment	  -­‐
equivalent	  to	  ABSOLUTE
2)	  SciClone -­‐mutation	  
clustering
3)	  Phylosub -­‐ Population	  
frequencies	  and	  
predicted	  phylogenetic	  
trees
A B
C
D
G
E F
SNV	  population	  
Frequencies
(time	  points	  ordered	   from	  
inner	   to	  outer	   circles)
Predicted	  
phylogenetic	  
trees
0
25
50
75
100
0 25 50 75 100
Mutation	  clustering
%VAF	  at	  TP1
%
VA
F	  a
t	  T
P2
M
et
ho
ds
Re
su
lts
SNVs
786	  somatically-­‐acquired	  
mutations	  (missense,	  
nonsense	  or	  frame-­‐
shift)*
CNAs
85	  acquired	  CNAs
Deletions	  =	  75
Gains	  =	  10
Validation	  of	  WES	  
findings
SNVs =	  224/312	  (72%)
Indels =	  27/474	  (5.7%)*
Indels (2+TPs)	   =	  7/9(78%)
Analysis	  of	  
temporal	  clonal	  
dynamics
Sub-­‐clonal	  population	  
structures	  before	  and	  
after	  1st line	  therapy:
Static	  (n=4)
Expanding	  (n=2)
Evolving	  (n=7)
Linear	  (n=4)	  or	  Branching	  
(n=9)	  evolution
7
Tx
Tx Tx
Tx
Tx
Tx
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Patient'ID
Tumour'timepoint TP1 TP2 TP1 TP2 TP1 TP2 TP3 TP1 TP2 TP3 TP1 TP2 TP3 TP1 TP2 TP3 TP1 TP2 TP1 TP2 TP1 TP2 TP3 TP4 TP1 TP2 TP1 TP2 TP1 TP2 TP3 TP1 TP2 TP3 TP4 TP5
Disease'Stage cMBL A cMBL A A A A A A C A A C A A B A A A A A A A A A B cMBL B A C B A A A A C
Years'from'diagnosis 1 7 3 10 1 6 9 0 9 10 1 4 6 0 3 7 5 11 7 15 0 3 8 10 5 11 3 6 1 3 8 0 8 9 10 11
del(13q14)
Trisomy'12
del(17p)
Established'Drivers ATM 52 49 49
BCOR
BIRC3 31 29 41 31
CHD2 67 58
DDX3X 77 2
EGR2
FBXW7
IRF4 0.13 41 39 47 41
ITPKB 9
KLHL6 55 47
KRAS
MED12
MUC4
Putative'CLL'Drivers MYD88 41 47
NFKBIE 29 21 25
NOTCH1 47 44 47 0.1 11 19 14 25
NRAS
POT1
RIPK1
SAMHD1
SF3B1 0.1 0.07 17 51 58
SPEN 52 38 46 35
TP53 0.1 29 0.1 0.1 0.4 3.3
XPO1
ZMYM3 13 33 49
mirF142 6
NOTCH1 '3'UTR
PAX5@enhancer'region SC C C C C SC C C
New'Genes BCL2 43 31 33 29
HEPH 80 1
ITGA6 30 36
LTF 11 33 42
RARB 21
TEC 34
TLR4 53 50 51
TNFAIP3 22 23 26
Multiple'ProductiveFIGH
Translocation t(4212) t(4212) t(7213) t(7213) t(6213) t(6213) t(12215)
del13q14'type I/II I/II II II II II I I I/II I/II I I I I II II I I I I I I I
Genome'complexity
137 8 115 9 121021 3 4 6
Recurrently	  
mutated	  CLL	  
genes
Hematological
Genes
SNP	  6.0
Treated	  diseaseUntreated	  disease
Patient-­‐13
Positive(result 47 Clonal(somatic(mutation 14 Subclonal(somatic(mutation Germline(variant
Gain Amplification(/(Trisomy12 Mono=allelic(loss Biallelic(loss
Key
Positive(result 47 Clonal(somatic(mutation 14 Subclonal(somatic(mutation Germline(variant
Gain Amplification(/(Trisomy12 Mono=allelic(loss Biallelic(loss
Positive(result 47 Cl nal(somatic(mutation 14 Subclonal(somatic(mutation Germline(v ria t
Gain Amplification(/(Trisomy12 Mono=allelic(loss Biallelic(lossPositive(result 47 Clonal(somatic(mutation 14 Subclonal(somatic(mutation Germ ine(variant
Gain Amplification(/(Trisomy12 Mono=allel c(loss Biallelic(loss
Positive(result 47 Clonal(somatic(mutation 14 Subclonal(somatic(mutation Germline(variant
Gain Amplification(/(Trisomy12 Mono=allelic(loss Biallelic(loss
Positive(result 47 Clonal(somatic(mutation 14 Subclonal(somatic(mutation Germline(variant
Gain Amplification(/(Trisomy12 Mono= llelic(loss Biallelic(lossPositive(result 47 Cl nal(so atic(mutation 14 Subclonal(somatic(mutation Germline(variant
G in Amplification(/(Trisomy12 Mono=allelic(loss Biallelic(loss
G i % % ri y%12 Amplification Mono6allelic%loss Biallelic%loss
Non-­‐coding	  
Mutation
Ch
ro
m
os
om
e
1
3
5
7
9
11
13
15
17
19
21
X
Y
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A B
Linear	  Evolution Branching	  Evolution
#9
0	  	  	  	  	  	  	  	  20	  	  	  	  	  	  	  40	  	  	  	  	  	  	  60	  	  	  	  	  	  	  	  80	  	  	  	  	  	  100
%	  VAF
FZD7,	  
BSN,	  
CTSO
MET,	  TIAM1,	  
ACO2	  
SOX14,	  
SERPINB2,	  
TSPEAR	  
BCL2
SPEN
TP4:	  TP53 (3.3%	  VAF)
0	  	  	  	  	  	  	  	  20	  	  	  	  	  	  	  40	  	  	  	  	  	  	  60	  	  	  	  	  	  	  80	  	  	  	  	  	  100
#6
%	  VAF
WAPAL,	  ASXL2,	  
TOMM
NOTCH1
ORC5,	  
TNFRSF10C,	  
ZMYM3
VRK3,	  TNRC6B,	  
JAKMIP1
SF3B1
STRIP2,	  CEP152,	  MYH11	  
TP1	  %	  VAF
(x-­‐axis)
TP2	  %	  VAF
(z-­‐axis)
(y
-­‐a
xis
)
TP
3	  
%
	  V
AF
0	  	  	  	  	  	  	  	  20	  	  	  	  	  	  	  40	  	  	  	  	  	  	  60	  	  	  	  	  	  	  80	  	  	  	  	  	  100
#12
0	  	  	  	  	  	  	  	  20	  	  	  	  	  	  	  40	  	  	  	  	  	  	  60	  	  	  	  	  	  	  80	  	  	  	  	  	  100
#4
MCCC1,	  PUF60,	  
SETD1B
ATM (x2),
WSCD2,
MAP3K3
PDE12	   (x2),	  
APC,	  EYS
PLCG1,	  TNFAIP3,	  
TSPAN33
SLCO1C1,	  WDR66,	  XPO6
%	  VAF %	  VAF
TP1	  %	  VAF
(x-­‐axis)
TP2	  %	  VAF
(z-­‐axis)
(y
-­‐a
xis
)
TP
3	  
%
	  V
AF
(x=y=z)
TP1=2=3
(x=y=z)
TP1=2=3
(A):	  BSN;	  CTSO;	  MAU2;	  OR4A5;	  SCEL;	  SH3RF1	  (B):BCL2;	  FZD7;	  SPEN	  (C):	  ALLC;	  ASB3,GPR75-­‐ASB3;	  
CEACAM19;	  DEGS1;	  MET;	  RWDD2A;	  SERPINB2;	  TIAM1;	  TSPEAR	  	  (D):	  ACBD7 (E):ACO2	  (F):	  TP53
(G):	  SOX14
A B
C
D
GTP1:1
TP2:1
TP3:1
TP4:1
E
.88
.79
.95
.84
.11
.36
.34
.32
.23
.04
.01
.02
.02
.04
.12
.21
.006
.001
.005
.03
F
*.14
.72
.93
.80
*
Sc
iC
lo
ne
Ph
yl
os
ub Mutations	  in	  each	  node
TP53	  
Mutations	  in	  each	  node
#9
(A):	  NOTCH1	  (B):	  ASXL2;	  CEP152;	  MYH11;	  PLXNA4;	  STRIP2;	  TOMM34;	  UNKL;	  WAPAL
(C):	  SPO11;	  NCOA2 (D):	  AKAP1;	  KIAA1549L;	  NAV2;	  TNFRSF10C;	  ORC5 (E):	  CEACAM1;	  EFNB2;	  JAKMIP1;	  
TDO2;	  TNRC6B;	  VRK3;	  ZMYM3 (F):	  SPOCK3 (G):	  KCTD8 (H):	  RAD50;	  HTR4 (I):	  ITPKB (J):	  SF3B1
A
B C
E
D
TP1:	  .96
TP2:	  .94
TP3:	  .98
.27
.66
.97
.66
.24
.004
.01
.04
.05
F G
H
I
J
.28
.17
.004
.002
.006
.27
.003
.003
.09
.13
.26
.12
.05
.10
.04
*
*	  .21
.47
.40
TP53	  
SF3B1
#6ZMYM3
SF3B1
Mutations	  in	  each	  node
B C DA E
TP1:	  1
TP2:	  1
TP3:	  1
.57
.48
.52
.38
.37
.26
.23
.37
.26
.17
.28
.18
ZMYM3	  
(A):	  APC;	  ATL3;	  EYS;	  HRH4;	  OR8K3;	  PDE12 (B):	  KIAA1217;	  TSPAN33;	  PLCG1;	  TNFAIP3	  (C):	  
XPO6;	  GBX2;	  TEX13B (D):	  MARK4;	  CSE1L;	  DNPEP;	  WDR66	  (E):	  SLCO1C1
Mutations	  in	  each	  node
(A):	  ATM	  (x2);	  CIRBP;	  PLCE1;	  TNRC18;	  WSCD2	   (B):	  MAP3K3;	  PKD1L1 (C):	  PUF60;	  KIAA1984
(D):	  SETD1B;	  SIM1;	  NSRP1 (E):	  MCCC1
TNFAIP3	  
TNFAIP3	  
TP1:	  1
TP2:	  1
TP3:	  1
.77
.87
.90
.005
.85
.89
.001
.65
.77
.0
.41
.60
#4 B C D
A E
ATM	  
ATM	  
#12
ITPKB	  
ITPKB	  
ITPKB
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Multiple(Productive/IGH 3"48 5"10"1*01
ATM$
NOTCH1$ 0.06 11 19 14 25
SF3B1$
TP53$
BIRC3$ 31 29 41 31
DDX3X$ 77 2
IRF4 41 39 47 41
SAMHD1$
HEPH 80 1
RARB 21
TEC 34
IL1RAPL2 86 3
POSTN 85 3
ANK3 43 2
GSTA4 43 3
FCRLB 42 2
HNRNPUL2 42 2
SHOC2 41 2
MBOAT1 37 1
HIST1H4D 34 1
LRP1B 33 2
SYTL2 28
CSNK2B 4
SPOCK3 1 1
RBMX 13 15 11 13 13
SLC25A5 6 7 5 6 7
FAM111B 4 4 4 4 4
RMDN3 2 3 1 3 4
RBM24 3 47 54 54 47
LNPEP 2 48 44 50 42
CSMD3 1 50 45 48 47
ZBBX 44 48 49 48
DPY19L3 42 45 47 44
SLC8A2 39 33 44 34
DSG4 35 33 41 32
CHAC2 34 36 46 41
BMP5 29 20 37 28
SREBF2 12 13 20 15
STRADA 6 10 3 8
ASTN1 4 7 2 8
A
D
B
C
TP1:	  1
TP2:	  1
TP3:	  1
TP4:	  1
TP5:	  1
EH
FG
*.02
.71
.63
.82
.76
.84
.14
.14
.07
.10
.05
.04
.05
.02
.002
.73
.04
.005
.008
.02
.05
.03
.07
.03
.04
.005
.34
.24
.43
.36
.004
.14
.19
.07
.11
M-­‐CLL
U-­‐CLL
*
B
C
ANK3;	  SYTL2;	  TEC;	  DDX3X;	  FCRLB;	  GSTA4;	  
HEPH;	  HIST1H4D;	  HNRNPUL2;	  IL1RAPL2;	  
LRP1B;	  MBOAT1;	  POSTN;	  SHOC2
Patient'ID
tumour'time'point TP1 TP2 TP3 TP4 TP5
Disease'Stage A A A A C
Years'from'diagnosis 0 8 9 10 11
Lymphocyte'count'(1x10^3'cells) 18 157 265 28 119
treated Chl/BR Of
del13q14
trisomy12
lti l ' r ctiv HI 3348 531031*01
$
T 53$
BIRC3$ 31 29 41 31
DDX3X$ 77 2
IRF4 41 39 47 41
SAMHD1$
HEPH 80 1
RARB 21
TEC 34
IL1RAPL2 86 3
POSTN 85 3
ANK3 43 2
GSTA4 43 3
FCRLB 2 2
HNRNPU 2
SHOC 1
MBOAT1 37 1
HIST1H4D 34 1
LRP1B 33 2
SYTL2 28
CSNK2B 4
SPOCK3 1 1
RBMX 13 15 11 13 13
SLC25A5 6 7 5 6 7
FAM111B 4 4 4 4 4
RMDN3 2 3 1 3 4
RBM24 3 47 54 54 47
LNPEP 2 48 44 50 42
CS D3 1 50 45 48 47
ZBBX 4 8 49 8
DPY19L 42 7 4
SLC8A2 39 33 4 34
DSG4 35 33 1 32
CHAC2 34 36 46 41
BMP5 29 20 37 28
SREBF2 12 13 20 15
STRADA 6 10 3 8
ASTN1 4 7 2 8
287
Established
Drivers
Putative	  
CLL	  Drivers
Hematological
Genes
SNP	  6.0 chr12
chr13
chrY
Other
Genes
0
100
0
200
Patient'ID
tumour'tim 'point TP1 TP2 TP3 TP4 TP5
Disease'Stage A A A A C
Years'from'diagnosis 0 8 9 10 11
Lymphocyte'count'(1x10^3'cells) 18 157 265 28 119
treated Chl/BR Of
del13q14
trisomy12
Multiple'ProductiveHIGH 3348 531031*01
ATM$
NOTCH1$ 0.06 11 19 14 25
SF3B1$
TP5 $
BIRC3$ 31 29 41 31
DDX3X$ 77 2
IRF4 41 39 47 41
SAMHD1$
HEPH 80 1
RARB 21
TEC 34
IL1RAPL2 86 3
POSTN 85
ANK3 43
GSTA4 43 3
FCRLB 42 2
HNRNPUL 42 2
SHOC2 41 2
MBOAT1 7
HIST1H4D 4 1
LRP1B 33 2
SYTL2 28
CSNK2B 4
SPOCK3 1 1
RBMX 13 15 11 13 13
SLC25A5 6 7 5 6 7
FA 111B 4 4 4 4
MDN3 2 3 1 3 4
RBM24 3 7 5 4 7
LNPEP 2 48 4 50 2
CSMD3 1 50 5 8 7
ZBBX 44 48 49 48
DPY19L3 42 45 7 4
SLC8A2 3 33 44 34
DSG4 35 3 41 32
CHAC2 34 36 46 41
BMP5 29 20 37 28
SREBF2 12 13 20 15
STRADA 6 10 3 8
ASTN1 4 7 2 8
287
Lymphocyte	  Count Trisomy12
del(13q14)
A
.80
.04
.003
.001
.004
.47
.01
.002
.001
.000
C0
C1
del(13q14)
M-­‐CLL
G F
E2
E1
Trisomy12
.02
.94
.93
.97
.90 .001
.73
.64
.84
.67
.0
.24
.37
.31
.40
.003
.12
.18
.03
.19
DPY19L3;	  IRF4;	  LNPEP;	  
ZBBX;	   RBM24;	  CSMD3	  
*
*
*
*
**
(A/B):	   empty	  WT	  node
(C):	  ANK3;	  SYTL2;	  TEC;	  DDX3X;	  FCRLB;	  GSTA4;	  HEPH;	  HIST1H4D;	  
HNRNPUL2;	   IL1RAPL2;	   LRP1B;	  MBOAT1;	  POSTN;	  RARB;	  SHOC2
(D):	  RBMX;	   FAM111B;	  SLC25A5;	  RMDN3;	  CSNK2B
(E):	  BIRC3;	   BMP5;	  CHAC2;	  CSMD3;	  DPY19L3;	  DSG4;	  IRF4;	  LNPEP;	  
ZBBX;	   NOTCH1;	  RBM24;	  SLC8A2
(F):	   SREBF2
(G):	   STRADA;	  ASTN1	  
(H):	   SPOCK3
RARB
(F):	  NOTCH1;	  SREBF2
(G):	   STRADA;	  ASTN1	  
SLC8A2;	  BIRC3;	  BMP5;	  
CHAC2;	  DSG4	  U-­‐CLL
***
***********
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